Polymyxins revisited - PubMed (original) (raw)
Review
Polymyxins revisited
David Landman et al. Clin Microbiol Rev. 2008 Jul.
Abstract
The global emergence of multidrug-resistant gram-negative bacilli has spurred a renewed interest in polymyxins. Once discarded due to concerns regarding nephrotoxicity and neurotoxicity, polymyxins now hold an important role in the antibiotic armamentarium. However, more reliable information is needed to determine the optimal dosing of these agents. Also, unanswered questions regarding in vitro testing remain, including questions regarding the reliability of automated systems and the establishment of appropriate breakpoints for defining susceptibility. Most contemporary clinical studies examining the use of these agents have involved patients with infections due to multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii strains. It has been reassuring that polymyxin therapy for resistant bacteria has resulted in clinical responses and toxicity rates similar to those for carbapenem therapy for susceptible isolates. While most surveillance studies demonstrated high rates of susceptibility, several reports noted the emergence of polymyxin-resistant nosocomial pathogens. Polymyxins have assumed an important antibiotic niche for therapy for hospital-acquired infections; further studies defining the optimal use of these agents will likely extend the duration of their clinical usefulness.
Similar articles
- Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).
Pogue JM, Jones RN, Bradley JS, Andes DR, Bhavnani SM, Drusano GL, Dudley MN, Flamm RK, Rodvold KA, Ambrose PG. Pogue JM, et al. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01495-19. doi: 10.1128/AAC.01495-19. Print 2020 Jan 27. Antimicrob Agents Chemother. 2020. PMID: 31767718 Free PMC article. - Polymyxin antibiotics for gram-negative infections.
Arnold TM, Forrest GN, Messmer KJ. Arnold TM, et al. Am J Health Syst Pharm. 2007 Apr 15;64(8):819-26. doi: 10.2146/ajhp060473. Am J Health Syst Pharm. 2007. PMID: 17420197 Review. - Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
Almangour TA, Garcia E, Zhou Q, Forrest A, Kaye KS, Li J, Velkov T, Rao GG. Almangour TA, et al. Int J Antimicrob Agents. 2021 Jun;57(6):106328. doi: 10.1016/j.ijantimicag.2021.106328. Epub 2021 Mar 27. Int J Antimicrob Agents. 2021. PMID: 33785362 - Polymyxins: Antimicrobial susceptibility concerns and therapeutic options.
Balaji V, Jeremiah SS, Baliga PR. Balaji V, et al. Indian J Med Microbiol. 2011 Jul-Sep;29(3):230-42. doi: 10.4103/0255-0857.83905. Indian J Med Microbiol. 2011. PMID: 21860102 Review. - Is it time to move away from polymyxins?: evidence and alternatives.
Soman R, Bakthavatchalam YD, Nadarajan A, Dwarakanathan HT, Venkatasubramanian R, Veeraraghavan B. Soman R, et al. Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):461-475. doi: 10.1007/s10096-020-04053-w. Epub 2020 Oct 2. Eur J Clin Microbiol Infect Dis. 2021. PMID: 33009595 Review.
Cited by
- Metabolic profiling unveils enhanced antibacterial synergy of polymyxin B and teixobactin against multi-drug resistant Acinetobacter baumannii.
Hussein M, Kang Z, Neville SL, Allobawi R, Thrombare V, Koh AJJ, Wilksch J, Crawford S, Mohammed MK, McDevitt CA, Baker M, Rao GG, Li J, Velkov T. Hussein M, et al. Sci Rep. 2024 Nov 7;14(1):27145. doi: 10.1038/s41598-024-78769-6. Sci Rep. 2024. PMID: 39511424 Free PMC article. - Alteration in the Morphological and Transcriptomic Profiles of Acinetobacter baumannii after Exposure to Colistin.
Yoon EJ, Mo JW, Kim JW, Jeong MC, Yoo JS. Yoon EJ, et al. Microorganisms. 2024 Aug 11;12(8):1644. doi: 10.3390/microorganisms12081644. Microorganisms. 2024. PMID: 39203486 Free PMC article. - Adjuvants restore colistin sensitivity in mouse models of highly colistin-resistant isolates, limiting bacterial proliferation and dissemination.
Koller BH, Jania LA, Li H, Barker WT, Melander RJ, Melander C. Koller BH, et al. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0067124. doi: 10.1128/aac.00671-24. Epub 2024 Aug 28. Antimicrob Agents Chemother. 2024. PMID: 39194205 - Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins.
Aysert-Yildiz P, Özgen-Top Ö, Şentürk AF, Kanik S, Özger HS, Dizbay M. Aysert-Yildiz P, et al. BMC Infect Dis. 2024 Aug 26;24(1):862. doi: 10.1186/s12879-024-09759-2. BMC Infect Dis. 2024. PMID: 39187812 Free PMC article.
References
- Ainsworth, G. C., A. M. Brown, and G. Brownlee. 1947. “Aerosporin”. An antibiotic produced by Bacillus aerosporus Greer. Nature 160:263. - PubMed
- Alothman, G. A., B. Ho., M. M. Alsaadi, S. L. Ho, L. O'Drowsky, E. Louca, and A. L. Coates. 2005. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 127:522-529. - PubMed
- Amsden, G. W. 2000. Tables of antimicrobial agent pharmacology, p. 551-601. In G. L. Mandel, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, PA.
- Antoniadou, A., F. Kontopidou, G. Poulakou, E. Koratzanis, I. Galani, E. Papadomichelakis, P. Kopterides, M. Souli, A. Armaganidis, and H. Giamarellou. 2007. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother. 59:786-790. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical